Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function.
The platelet glycoprotein (GP) IIb/IIIa inhibitors differ markedly in their pharmacokinetics, pharmacodynamics, and differential receptor affinities. Abciximab and the small-molecule GP IIb/IIIa inhibitors (eptifibatide, tirofiban) have separate, distinct binding sites on the GP IIb/IIIa receptor complex. The affinity of abciximab for the platelet GP IIb/IIIa integrin receptor, together with non-platelet-receptor mediated effects achieved through its affinity for the aVb3 and CD11b/18 receptors, most likely contribute to the clinical benefit associated with the use of abciximab as adjunctive pharmacotherapy during primary percutaneous coronary intervention for the treatment of ST-elevation acute myocardial infarction.
Kereiakes
Dean J
DJ
Heart Center of Greater Cincinnati, Cincinnati, Ohio, USA.
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D003326:Coronary Circulation / Q000187:drug effects*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors; D016177:Macrophage-1 Antigen / Q000187:drug effects; D008833:Microcirculation / Q000187:drug effects; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014657:Vasculitis / Q000209:etiology / Q000517:prevention & control*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D039302:Integrin alphaVbeta3; D016177:Macrophage-1 Antigen; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab